Targeting glyco-immune checkpoints for cancer therapy

References

• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018 Sep;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open. 2019 May 3;2(5):e192535.
   PubMed Web of Science ®Google Scholar
• Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019 Nov;575(7782):299–309.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017 Feb 9;168(4):707–723.
   PubMed Web of Science ®Google Scholar
• Varki A. Biological roles of glycans. Glycobiology. 2017 Jan;27(1):3–49.
   PubMed Web of Science ®Google Scholar
• Schjoldager KT, Narimatsu Y, Joshi HJ, et al. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020 Oct 21;21:729–749.
   PubMed Web of Science ®Google Scholar
• Rodrigues Mantuano N, Natoli M, Zippelius A, et al. Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. J Immunother Cancer. 2020 Oct;8(2):e001222.
   PubMed Web of Science ®Google Scholar
• Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006 Sep 8;126(5):855–867.
   PubMed Web of Science ®Google Scholar
• Varki A, Kannagi R, Toole B, et al. Glycosylation changes in cancer. In: Essentials of glycobiology. Harbor (NY): Cold Spring; 2015. p. 597–609.
   Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015 Sep;15(9):540–555.
   PubMed Web of Science ®Google Scholar
• Hauselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 2014;4:28.
   PubMedGoogle Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015 Apr 13;27(4):450–461.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced Melanoma. N Engl J Med. 2019 Oct 17;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020–2031.
   PubMed Web of Science ®Google Scholar
• Barenwaldt A, Laubli H. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity. Expert Opin Ther Targets. 2019 Oct;23(10):839–853.
   PubMed Web of Science ®Google Scholar
• van de Wall S, Santegoets KCM, van Houtum EJH, et al. Sialoglycans and siglecs can shape the tumor immune microenvironment. Trends Immunol. 2020 Apr;41(4):274–285.
   PubMed Web of Science ®Google Scholar
• Mereiter S, Balmana M, Campos D, et al. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell. 2019 Jul 8;36(1):6–16.
   PubMed Web of Science ®Google Scholar
• Pearce OM, Laubli H. Sialic acids in cancer biology and immunity. Glycobiology. 2016 Feb;26(2):111–128.
   PubMed Web of Science ®Google Scholar
• Varki A. Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them. Glycobiology. 2011 Sep;21(9):1121–1124.
   PubMed Web of Science ®Google Scholar
• Shaw L, Schauer R. The biosynthesis of N-glycoloylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid. Biol Chem Hoppe-Seyler. 1988 Jun;369(6):477–486.
   PubMed Web of Science ®Google Scholar
• Irie A, Koyama S, Kozutsumi Y, et al. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem. 1998 Jun 19;273(25):15866–15871.
   PubMed Web of Science ®Google Scholar
• Muchmore EA, Diaz S, Varki A. A structural difference between the cell surfaces of humans and the great apes. Am J Phys Anthropol. 1998 Oct;107(2):187–198.
   PubMed Web of Science ®Google Scholar
• Tangvoranuntakul P, Gagneux P, Diaz S, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12045–12050.
   PubMed Web of Science ®Google Scholar
• Bardor M, Nguyen DH, Diaz S, et al. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem. 2005 Feb 11;280(6):4228–4237.
   PubMed Web of Science ®Google Scholar
• Samraj AN, Pearce OM, Laubli H, et al. A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):542–547.
   PubMed Web of Science ®Google Scholar
• Blanco R, Rengifo CE, Cedeno M, et al. Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Patholog Res Int. 2012;2012:235418.
   PubMedGoogle Scholar
• Blanco R, Rengifo E, Cedeno M, et al. Immunoreactivity of the 14F7 mab raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol. 2011;2011:645641.
   PubMedGoogle Scholar
• Blanco R, Rengifo E, Rengifo CE, et al. Immunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-Glycolyl GM3 ganglioside in some benign and malignant skin neoplasms. ISRN Dermatol. 2011;2011:848909.
   PubMedGoogle Scholar
• Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020 Apr;26(38):365–395.
   Google Scholar
• Kelm S, Gerlach J, Brossmer R, et al. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med. 2002 May 6;195(9):1207–1213.
   PubMed Web of Science ®Google Scholar
• Jin L, McLean PA, Neel BG, et al. Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med. 2002 May 6;195(9):1199–1205.
   PubMed Web of Science ®Google Scholar
• Ikehara Y, Ikehara SK, Paulson JC. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem. 2004 Oct 8;279(41):43117–43125.
   PubMed Web of Science ®Google Scholar
• Kannagi R, Sakuma K, Miyazaki K, et al. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. Cancer Sci. 2010 Mar;101(3):586–593.
   PubMed Web of Science ®Google Scholar
• Dall’Olio F, Malagolini N, Trinchera M, et al. Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression. Biochim Biophys Acta. 2014 Sep;1840(9):2752–2764.
   PubMed Web of Science ®Google Scholar
• Bull C, Boltje TJ, Balneger N, et al. Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity. Cancer Res. 2018 Jul 1;78(13):3574–3588.
   PubMed Web of Science ®Google Scholar
• Xiao H, Woods EC, Vukojicic P, et al. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10304–10309.
   PubMed Web of Science ®Google Scholar
• Gray MA, Stanczak MA, Mantuano NR, et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat Chem Biol. 2020 Dec;16(12):1376–1384.
   PubMed Web of Science ®Google Scholar
• Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996 Dec 1;56(23):5309–5318.
   PubMed Web of Science ®Google Scholar
• Shinoura N, Dohi T, Kondo T, et al. Ganglioside composition and its relation to clinical data in brain tumors. Neurosurgery. 1992 Sep;31(3):541–549.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Chiba H, Kuronuma K, et al. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci. 2013 Jan;104(1):43–47.
   PubMed Web of Science ®Google Scholar
• Popa I, Pons A, Mariller C, et al. Purification and structural characterization of de-N-acetylated form of GD3 ganglioside present in human melanoma tumors. Glycobiology. 2007 Apr;17(4):367–373.
   PubMed Web of Science ®Google Scholar
• Lahera T, Calvo A, Torres G, et al. Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer. J Oncol. 2014;2014:482301.
   PubMedGoogle Scholar
• Yin J, Hashimoto A, Izawa M, et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res. 2006 Mar 15;66(6):2937–2945.
   PubMed Web of Science ®Google Scholar
• Dorvignit D, Boligan KF, Relova-Hernandez E, et al. Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells. Sci Rep. 2019 Jul 9;9(1):9921.
   PubMedGoogle Scholar
• Adams OJ, Stanczak MA, von Gunten S, et al. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology. 2018 Sep 1;28(9):640–647.
   PubMed Web of Science ®Google Scholar
• Stanczak MA, Siddiqui SS, Trefny MP, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018 Nov 1;128(11):4912–4923.
   PubMed Web of Science ®Google Scholar
• Haas Q, Boligan KF, Jandus C, et al. Siglec-9 regulates an effector memory CD8(+) T-cell subset that congregates in the melanoma tumor microenvironment. Cancer Immunol Res. 2019 May;7(5):707–718.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019 Apr;25(4):656–666.
   PubMed Web of Science ®Google Scholar
• Beatson R, Tajadura-Ortega V, Achkova D, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016 Nov;17(11):1273–1281.
   PubMed Web of Science ®Google Scholar
• Laubli H, Pearce OM, Schwarz F, et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14211–14216.
   PubMed Web of Science ®Google Scholar
• Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019 Aug;572(7769):392–396.
   PubMed Web of Science ®Google Scholar
• Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014 Jan;10(1):69–75.
   PubMed Web of Science ®Google Scholar
• Jandus C, Boligan KF, Chijioke O, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 2014 Apr;124(4):1810–1820.
   PubMed Web of Science ®Google Scholar
• Girotti MR, Salatino M, Dalotto-Moreno T, et al. Sweetening the hallmarks of cancer: galectins as multifunctional mediators of tumor progression. J Exp Med. 2020 Feb 3;217(2). DOI:10.1084/jem.20182041.
   PubMed Web of Science ®Google Scholar
• Cummings RD, Liu FT, Vasta GR, et al. Galectins. In: Rd, Varki A, Cummings RD, editors. Essentials of glycobiology. Harbor (NY): Cold Spring; 2015. p. 469–480.
   Google Scholar
• Petit AE, Demotte N, Scheid B, et al. A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion. Nat Commun. 2016 Jul 22;7:12242.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Toscano MA. Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009 May;9(5):338–352.
   PubMed Web of Science ®Google Scholar
• Orozco CA, Martinez-Bosch N, Guerrero PE, et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3769–E3778.
   PubMed Web of Science ®Google Scholar
• Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 2004 Mar;5(3):241–251.
   PubMed Web of Science ®Google Scholar
• Dalotto-Moreno T, Croci DO, Cerliani JP, et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 2013 Feb 1;73(3):1107–1117.
   PubMed Web of Science ®Google Scholar
• Baker GJ, Chockley P, Yadav VN, et al. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res. 2014 Sep 15;74(18):5079–5090.
   PubMed Web of Science ®Google Scholar
• Verschuere T, Toelen J, Maes W, et al. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer. 2014 Feb 15;134(4):873–884.
   PubMed Web of Science ®Google Scholar
• Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014 Feb 13;156(4):744–758.
   PubMed Web of Science ®Google Scholar
• Demotte N, Bigirimana R, Wieers G, et al. A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes. Clin Cancer Res. 2014 Apr 1;20(7):1823–1833.
   PubMed Web of Science ®Google Scholar
• Demotte N, Stroobant V, Courtoy PJ, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity. 2008 Mar;28(3):414–424.
   PubMed Web of Science ®Google Scholar
• Demotte N, Wieers G, Van Der Smissen P, et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 2010 Oct 1;70(19):7476–7488.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol. 2015 Jan;15(1):45–56.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019 Nov;20(11):1425–1434.
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Sugiura D, Okazaki IM, et al. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020 Sep;8:2.
   Web of Science ®Google Scholar
• Wang W, Guo H, Geng J, et al. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J Biol Chem. 2014 Nov 28;289(48):33311–33319.
   PubMed Web of Science ®Google Scholar
• Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020 Mar;20(3):173–185.
   PubMed Web of Science ®Google Scholar
• Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020 Jun;8(1):e000911.
   PubMed Web of Science ®Google Scholar
• Goncalves Silva I, Yasinska IM, Sakhnevych SS, et al. The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017 Aug;22:44–57.
   PubMed Web of Science ®Google Scholar
• Wu C, Thalhamer T, Franca RF, et al. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity. 2014 Aug 21;41(2):270–282.
   PubMed Web of Science ®Google Scholar
• Demetriou M, Granovsky M, Quaggin S, et al. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature. 2001 Feb 8;409(6821):733–739.
   PubMed Web of Science ®Google Scholar
• Cummings RD, McEver RP. C-Type Lectins. In: Rd, Varki A, Cummings RD, editors. Essentials of Glycobiology. Harbor (NY): Cold Spring; 2015. p. 435–452.
   Google Scholar
• Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol. 2010 Jun;20(3):169–177.
   PubMed Web of Science ®Google Scholar
• Borsig L. Selectins in cancer immunity. Glycobiology. 2018 Sep 1;28(9):648–655.
   PubMed Web of Science ®Google Scholar
• Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996 Nov 1;88(9):3259–3287.
   PubMed Web of Science ®Google Scholar
• Laubli H, Spanaus KS, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009 Nov 12;114(20):4583–4591.
   PubMed Web of Science ®Google Scholar
• Tinoco R, Carrette F, Barraza ML, et al. PSGL-1 Is an immune checkpoint regulator that promotes T cell exhaustion. Immunity. 2016 May 17;44(5):1190–1203.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Su LJ, Pinckney J, et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature. 2019 Oct;574(7779):565–570.
   PubMed Web of Science ®Google Scholar
• van Vliet SJ, Gringhuis SI, Geijtenbeek TB, et al. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat Immunol. 2006 Nov;7(11):1200–1208.
   PubMed Web of Science ®Google Scholar
• van Gisbergen KP, Aarnoudse CA, Meijer GA, et al. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res. 2005 Jul 1;65(13):5935–5944.
   PubMed Web of Science ®Google Scholar
• Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell. 2018 Jan 25;172(3):564–577 e13.
   PubMed Web of Science ®Google Scholar
• Baron J, Wang ES. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018 Jun;11(6):549–559.
   PubMed Web of Science ®Google Scholar
• Walter RB. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs. 2018 Apr;27(4):339–348.
   PubMed Web of Science ®Google Scholar
• Kouo T, Huang L, Pucsek AB, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015 Apr;3(4):412–423.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005 Dec;6(12):1245–1252.
   PubMed Web of Science ®Google Scholar
• Compagno D, Tiraboschi C, Garcia JD, et al. Galectins as checkpoints of the immune system in cancers, their clinical relevance, and implication in clinical trials. Biomolecules. 2020 May 12;10(5):750.
   Web of Science ®Google Scholar
• Dellon ES, Peterson KA, Murray JA, et al. Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med. 2020 Oct 22;383(17):1624–1634.
   PubMed Web of Science ®Google Scholar
• Youngblood BA, Leung J, Falahati R, et al. Discovery, function, and therapeutic targeting of siglec-8. Cells. 2020 Dec 24;10(1):19.
   Web of Science ®Google Scholar
• Schanin J, Gebremeskel S, Korver W, et al. A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation. Mucosal Immunol. 2020 Aug 19. DOI:10.1038/s41385-020-00336-9.
   PubMed Web of Science ®Google Scholar
• Yokoi H, Choi OH, Hubbard W, et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol. 2008 Feb;121(2):499–505 e1.
   PubMed Web of Science ®Google Scholar
• Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics. 2019;13:1–12.
   PubMed Web of Science ®Google Scholar
• Segatori VI, Cuello HA, Gulino CA, et al. Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients. Cancer Immunol Immunother. 2018 Aug;67(8):1285–1296.
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Garrigues HJ, Garrigues U, et al. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 1990 Apr 1;50(7):2183–2190.
   PubMed Web of Science ®Google Scholar
• Scott AM, Geleick D, Rubira M, et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res. 2000 Jun 15;60(12):3254–3261.
   PubMed Web of Science ®Google Scholar
• Danielczyk A, Stahn R, Faulstich D, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother. 2006 Nov;55(11):1337–1347.
   PubMed Web of Science ®Google Scholar
• Fiedler W, DeDosso S, Cresta S, et al. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Eur J Cancer. 2016 Aug;63:55–63.
   PubMed Web of Science ®Google Scholar
• Lavrsen K, Madsen CB, Rasch MG, et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J. 2013 Apr;30(3):227–236.
   PubMed Web of Science ®Google Scholar
• Macauley MS, Arlian BM, Rillahan CD, et al. Systemic blockade of sialylation in mice with a global inhibitor of sialyltransferases. J Biol Chem. 2014 Dec 19;289(51):35149–35158.
   PubMed Web of Science ®Google Scholar
• Vuong L, Kouverianou E, Rooney CM, et al. An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res. 2019 Apr 1;79(7):1480–1492.
   PubMed Web of Science ®Google Scholar
• Swindall AF, Bellis SL. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem. 2011 Jul 1;286(26):22982–22990.
   PubMed Web of Science ®Google Scholar
• Cohen M, Elkabets M, Perlmutter M, et al. Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting. J Immunol. 2010 Nov 15;185(10):5869–5878.
   PubMed Web of Science ®Google Scholar
• Varki A, Gagneux P. Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci. 2012 Apr;1253:16–36.
   PubMed Web of Science ®Google Scholar
• Feng M, Marjon KD, Zhu F, et al. Programmed cell removal by calreticulin in tissue homeostasis and cancer. Nat Commun. 2018 Aug 10;9(1):3194.
   PubMedGoogle Scholar
• Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014 Oct;14(10):653–666.
   PubMed Web of Science ®Google Scholar
• Attrill H, Takazawa H, Witt S, et al. The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design. Biochem J. 2006 Jul 15;397(2):271–278.
   PubMedGoogle Scholar
• Yamaji T, Teranishi T, Alphey MS, et al. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J Biol Chem. 2002 Feb 22;277(8):6324–6332.
   PubMed Web of Science ®Google Scholar
• Hinderlich S, Weidemann W, Yardeni T, et al. UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE): a master regulator of sialic acid synthesis. Top Curr Chem. 2015;366:97–137.
   PubMed Web of Science ®Google Scholar
• Collins BE, Smith BA, Bengtson P, et al. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol. 2006 Feb;7(2):199–206.
   PubMed Web of Science ®Google Scholar
• Duan S, Koziol-White CJ, Jester WF Jr., et al. CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen. J Clin Invest. 2019 Mar 1;129(3):1387–1401.
   PubMed Web of Science ®Google Scholar
• Rodrigues E, Jung J, Park H, et al. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands. Nat Commun. 2020 Oct 9;11(1):5091.
   PubMed Web of Science ®Google Scholar